Immunoassay News and Research

RSS

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

NMS Labs launches unique test for Methotrexate

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.

8 Feb 2011

AB SCIEX, ARUP enter collaboration to develop new clinical research test methods for hormone analysis

AB SCIEX, a global leader in life science analytical technologies, today announced a collaboration with ARUP Laboratories, a major clinical reference laboratory in the United States, to develop new test methods that clinical research laboratories around the world can adopt to improve hormone analysis.

7 Feb 2011

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Avantra Biosciences today announced the selection of TGen Drug Development as a key test site for Avantra's new biomarker quantitation platform.

1 Feb 2011

Avantra begins shipment of new Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay

Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx™ BioChip Immunoassay.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Meridian Bioscience first quarter net sales decrease 12% to $37.3 million

Net sales for the first quarter of fiscal 2011 were $37,263,000 as compared to $42,457,000 for the same period of the prior fiscal year, a decrease of 12%. Net earnings for the first quarter of fiscal 2011 were $6,025,000, or $0.15 per diluted share, both decreases of 32% from the first quarter of fiscal 2010. Diluted common shares outstanding for the first quarter of fiscal 2011 and 2010 were 41,294,000 and 41,185,000, respectively.

20 Jan 2011

Vermillion receives USPTO patent for PAD biomarker

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued patent number 7,867,719 entitled "Beta-2 microglobulin as a biomarker for peripheral artery disease" to the Company.

12 Jan 2011

FDA grants marketing clearance for diaDexus's PLAC Test

diaDexus, a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that the U.S. Food and Drug Administration has cleared for marketing the automated version of its proprietary PLAC® Test.

9 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

Response Biomedical strengthens patent protection for RAMP technology

Response Biomedical Corporation today announced that the United States Patent and Trademark Office issued an official Notice of Allowance on one of the Company's patent applications regarding the RAMP® technology. The patent entitled "Comparative Multiple Analyte Immunoassay" is expected to issue in the first quarter of 2011.

20 Dec 2010

Gen-Probe announces GTI Diagnostics acquisition from Riverside Company

Gen-Probe Incorporated announced today that the Company has acquired GTI Diagnostics, a privately held specialty diagnostics company focused on the transplantation, blood bank and specialty coagulation markets, for $53 million in cash.

17 Dec 2010

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

13 Dec 2010

MP receives FDA IND approval for clinical trial with HTLV-I/II ELISA 4.0 and HTLV Blot.2.4

MP Biomedicals LLC announced today that it has received approval of its investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to start pivotal clinical trials in the USA with the MP Diagnostics™ HTLV-I/II ELISA 4.0 and HTLV Blot.2.4. Studies will be conducted within the American Red Cross, the California Department of Public Health, and LABS, Inc. The company is working closely with the principal investigator of the American Red Cross sites, Dr. Susan Stramer, Executive Scientific Officer.

From MP Biomedicals, LLC 7 Dec 2010

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon's comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

1 Dec 2010

New ELISA protocol for Midkine detection in blood serum

BioGenes GmbH, a supplier of GMP compliant immunoassay and antibody services, has developed and optimized the first ever fully validated ELISA protocol for Midkine detection in blood serum.

16 Nov 2010

Meridian fourth quarter net sales decrease 16% to $35.5 million

Meridian Bioscience, Inc., reported fourth quarter and full-year fiscal 2010 net sales of $35.5 million and $143.0 million, respectively, decreases of 16% and 4%, respectively, from the same periods of the prior fiscal year.

11 Nov 2010

Roche announces U.S. introduction of cobas e 602 analyzer

Roche announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas 8000 modular analyzer series for diagnostic labs with high-volume workloads. Labs will now be able to combine this new immunoassay module with two existing clinical chemistry modules to create an integrated platform with 24 unique system configurations to match their specific testing needs.

From Roche Sequencing and Life Science 30 Oct 2010

IBI receives U.S. patent for novel blood protein biomarkers

Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

28 Oct 2010

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.

14 Oct 2010